American venture funds invest $6,000,000,000 in biotechnology and artificial intelligence

Flagship Pioneering, the American venture capital fund known for launching Moderna Inc., plans to create a series of biotechnology companies that will use artificial intelligence in drug development. In its latest investment round, Flagship raised $3,600,000,000, including $2,600,000,000 for its eighth fund, and intends to raise additional funds this year to reach a total goal of $3,000,000,000. Over the next three years, the fund plans to invest in projects to develop chemical materials for drugs and automate scientific hypotheses using AI.

Flagship is not the only one actively investing in biotechnology and AI. Earlier this year, the venture capital fund Arch Venture Partners began an investment round of $3,000,000,000, and the fund Index Ventures raised $2,300,000,000 for investments in breakthrough AI technologies. Of this amount, $800,000,000 is designated for investments in early-stage startups, while the remaining funds are for more mature companies.

Venture capital funds see enormous potential in using artificial intelligence to transform biotechnology and other sectors of the economy, actively attracting and investing significant funds in these areas.

Source: markets.ft